326 results on '"Lacut K"'
Search Results
152. Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study.
- Author
-
Heraudeau A, Delluc A, Le Henaff M, Lacut K, Leroyer C, Desrues B, Couturaud F, and Tromeur C
- Subjects
- Aged, Case-Control Studies, Female, Humans, Male, Middle Aged, Prognosis, Risk Assessment, Risk Factors, Venous Thromboembolism blood, Venous Thromboembolism etiology, Factor V genetics, Mutation, Neoplasms complications, Venous Thromboembolism diagnosis
- Abstract
Background: Cancer and factor V Leiden mutation are both risk factors for venous thromboembolism (VTE). Cancer critically increases the thrombotic risk whereas Factor V Leiden is the most common pro-thrombotic mutation. The impact of the factor V Leiden on the risk of VTE in cancer patients remains uncertain., Objective: To assess the impact of factor V Leiden mutation in cancer-associated thrombosis., Methods: The EDITH hospital-based case-control study enrolled 182 patients with cancer and VTE as well as 182 control patients with cancer, matched for gender, age and cancer location, between 2000 and 2012, in the University Hospital of Brest. All cases and controls were genotyped for the factor V Leiden mutation and interviewed with a standardized questionnaire., Results: Twenty one of 182 (11.5%) patients with cancer-associated thrombosis carried the factor V Leiden mutation and 4 of 182 (2.2%) controls with cancer but no venous thrombosis. In multivariate analysis including cancer stage and family history of VTE, cancer patients with factor V Leiden mutation had a seven-fold increased risk of venous thromboembolism (adjusted odds ratio [OR], 7.04; 95% CI, 2.01-24.63)., Conclusion: The pro-thrombotic Factor V Leiden mutation was found to be an independent additional risk factor for venous thromboembolism in cancer patients and might therefore be considered in the individual thrombotic risk assessment., Competing Interests: The authors have declared that no competing interests exist. Funding sources had no role relating to: the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2018
- Full Text
- View/download PDF
153. [Direct oral anticoagulants].
- Author
-
Le Mao R, Tromeur C, Fofana A, Leroyer C, and Lacut K
- Subjects
- Administration, Oral, Anticoagulants administration & dosage
- Abstract
Competing Interests: R. Le Mao et C. Tromeur déclarent des liens ponctuels (interventions et/ou congrès) avec Bayer, MSD et Apsen. A. Fofana déclare avoir été prise en charge lors de congrès par Pfizer. C. Leroyer et F. Couturaud déclarent des liens ponctuels (interventions et congrès) avec BMS, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Actelion, Sanofi, GSK, Novartis, K. Lacut déclare des liens ponctuels (interventions et/ou congrès) avec Bayer HealthCare, Pfizer et BMS.
- Published
- 2018
154. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).
- Author
-
Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, and Ianotto JC
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Female, Fibrinolytic Agents therapeutic use, Humans, Male, Middle Aged, Polycythemia Vera complications, Risk Factors, Surveys and Questionnaires, Thrombocythemia, Essential complications, Medication Adherence statistics & numerical data, Polycythemia Vera drug therapy, Thrombocythemia, Essential drug therapy
- Abstract
The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive drugs for polycythemia vera or essential thrombocythemia were recruited at our institution ( Observatoire Brestois des Néoplasies Myéloprolifératives registry). They completed a one-shot questionnaire designed by investigators ( Etude de l'Observance Thérapeutique et des Effets Secondaires des Traitements study). Data about complications (thrombosis, transformation and death) at any time in the patient's life (before diagnosis, up until consultation and after the completion of the questionnaire) were collected. Sixty-five (22.7%) of 286 patients reported poor adherence (<90%) to their treatment with cytoreductive drugs and 46/255/18%) also declared non-adherence to antithrombotic drugs. In total, 85/286 patients (29.7%) declared they did not adhere to their treatment. Missing an intake was rare and was mostly due to forgetfulness especially during occupational travel and holidays. Patients who did not adhere to their treatment were characterized by younger age, living alone, having few medications but a high numbers of pills and determining their own schedule of drug intake. Having experienced thrombosis or hematologic evolution did not influence the adherence rate. Non-adherence to oral therapy was associated with a higher risk of phenotypic evolution (7.3 versus 1.8%, P =0.05). For patients treated for polycythemia vera or essential thrombocythemia, non-adherence to cytoreductive and/or antithrombotic therapies is frequent and is influenced by age, habitus and concomitant treatments, but not by disease history or treatment side effects. Phenotypic evolution seems to be more frequent in the non-adherent group., (Copyright© 2018 Ferrata Storti Foundation.)
- Published
- 2018
- Full Text
- View/download PDF
155. Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study.
- Author
-
Delluc A, Ianotto JC, Tromeur C, De Moreuil C, Couturaud F, Lacut K, Le Moigne E, Louis P, Thereaux J, Metges JP, and Mottier D
- Subjects
- Aged, Female, Humans, Incidence, Male, Neoplasms pathology, Risk Factors, Early Detection of Cancer methods, Neoplasms etiology, Venous Thrombosis complications
- Abstract
Background: Venous thromboembolism (VTE) can be the first manifestation of cancer; however, the current incidence of malignancy in unselected patients with first unprovoked VTE needs to be confirmed., Material and Methods: Between March 1st, 2013 and February 28th, 2015 we included and followed-up all patients living in the Brest district, France, who were seen in hospitals or the community for a first symptomatic unprovoked VTE event. The primary study outcome was the one-year incidence of cancer., Results: 526 patients, mean age 66.6 ± 18.1 years, 246 (46.8%) men, were included in the study. In the year following VTE, 26 patients were diagnosed with cancer, corresponding to a one-year cumulative incidence of cancer of 5.06% (95% CI 3.47-7.35). Age ≥60, smoking and pulmonary embolism were significantly associated with cancer diagnosis in multivariate analysis. Fifty percent of cancers were patent at the time of VTE diagnosis, mostly detected on CTPA (Computed Tomographic Pulmonary Angiography) performed for pulmonary embolism assessment. After excluding patients with patent cancer at VTE diagnosis, the one-year incidence of cancer was 2.65% (95% CI: 1.55-4.52); in multivariate analysis, only current smoking was independently associated with a significant 5.4-fold increased risk for cancer diagnosis (HR 5.40; 95% CI 1.31-22.27). No cancer was diagnosed in patients aged 50 years or younger., Conclusion: The one-year incidence of cancer after a first unprovoked VTE was 5.06%. Half of the cancers were diagnosed during the diagnosis procedure for pulmonary embolism using CTPA., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
156. Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial.
- Author
-
Tromeur C, Sanchez O, Presles E, Pernod G, Bertoletti L, Jego P, Duhamel E, Provost K, Parent F, Robin P, Deloire L, Leven F, Mingant F, Bressollette L, Le Roux PY, Salaun PY, Nonent M, Pan-Petesch B, Planquette B, Girard P, Lacut K, Melac S, Mismetti P, Laporte S, Meyer G, Mottier D, Leroyer C, and Couturaud F
- Subjects
- Aged, Antibodies, Antiphospholipid blood, Anticoagulants therapeutic use, Double-Blind Method, Female, Follow-Up Studies, Humans, Lung physiopathology, Male, Middle Aged, Multivariate Analysis, Perfusion, Proportional Hazards Models, Pulmonary Embolism complications, Recurrence, Risk Factors, Venous Thromboembolism complications, Warfarin therapeutic use, Pulmonary Embolism diagnosis, Venous Thromboembolism diagnosis
- Abstract
We aimed to identify risk factors for recurrent venous thromboembolism (VTE) after unprovoked pulmonary embolism.Analyses were based on the double-blind randomised PADIS-PE trial, which included 371 patients with a first unprovoked pulmonary embolism initially treated during 6 months who were randomised to receive an additional 18 months of warfarin or placebo and followed up for 2 years after study treatment discontinuation. All patients had ventilation/perfusion lung scan at inclusion ( i.e. at 6 months of anticoagulation).During a median follow-up of 41 months, recurrent VTE occurred in 67 out of 371 patients (6.8 events per 100 person-years). In main multivariate analysis, the hazard ratio for recurrence was 3.65 (95% CI 1.33-9.99) for age 50-65 years, 4.70 (95% CI 1.78-12.40) for age >65 years, 2.06 (95% CI 1.14-3.72) for patients with pulmonary vascular obstruction index (PVOI) ≥5% at 6 months and 2.38 (95% CI 1.15-4.89) for patients with antiphospholipid antibodies. When considering that PVOI at 6 months would not be available in practice, PVOI ≥40% at pulmonary embolism diagnosis (present in 40% of patients) was also associated with a 2-fold increased risk of recurrence.After a first unprovoked pulmonary embolism, age, PVOI at pulmonary embolism diagnosis or after 6 months of anticoagulation and antiphospholipid antibodies were found to be independent predictors for recurrence., Competing Interests: Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com, (Copyright ©ERS 2018.)
- Published
- 2018
- Full Text
- View/download PDF
157. Association between statin exposure and venous thromboembolism risk in cancer patients. Data from the EDITH case-control study.
- Author
-
De Moreuil C, Le Mao R, Tromeur C, Couturaud F, Lacut K, and Delluc A
- Subjects
- Aged, Case-Control Studies, Female, Humans, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Neoplasms complications, Venous Thromboembolism prevention & control
- Published
- 2017
- Full Text
- View/download PDF
158. Association between hospitalization for acute medical illness and VTE risk: A lower efficacy of thromboprophylaxis in elderly patients? Results from the EDITH case-control study.
- Author
-
Hemon F, Fouchard F, Tromeur C, Lacut K, Le Gal G, Mottier D, Couturaud F, and Delluc A
- Subjects
- Aged, Aged, 80 and over, Case-Control Studies, Female, France epidemiology, Humans, Logistic Models, Male, Middle Aged, Risk Factors, Acute Disease therapy, Anticoagulants therapeutic use, Hospitalization statistics & numerical data, Venous Thromboembolism epidemiology, Venous Thromboembolism prevention & control
- Abstract
Introduction: Whether the association between hospitalization and venous thromboembolism (VTE) is modified by the use of thromboprophylaxis in older patients remains insufficiently evaluated. Our objective was to estimate VTE risk associated with hospitalization for acute medical illness depending on prescription of pharmacological thromboprophylaxis, in two different age categories using a 75years cutoff., Methods: Using a case-control design, we estimated the risk for symptomatic VTE associated with hospitalization for acute medical illness depending on prescription of pharmacological thromboprophylaxis in two different age categories using a 75 years cut-off., Results: 750 symptomatic VTE cases and their 750 age and sex-matched controls were analyzed. A total of 145 cases (19.3%) and 91 controls (12.1%) were hospitalized for acute medical illness in the preceding 3months prior to inclusion in the study (p<0.001). Hospitalization for acute medical illness was associated with a 75% increase in VTE risk: OR 1.75 (95% CI: 1.32-2.33). In patients <75years, there was a 2-fold increase in VTE risk associated with hospitalization when thromboprophylaxis was not prescribed: OR 2.01 (95% CI: 1.11-3.62), whereas no association was found when thromboprophylaxis was prescribed: OR 0.93 (95% CI: 0.44-1.95). In patients ≥75years, VTE risk associated with hospitalization remained significant whether or not thromboprophylaxis was prescribed: OR 2.69 (95% CI 1.28-5.66) and OR 2.02 (95% CI: 1.01-4.03) respectively., Conclusion: Our results suggest that VTE prevention in acutely ill medical patients may be less effective in patients ≥75years. This finding needs to be addressed in further studies., (Copyright © 2017. Published by Elsevier B.V.)
- Published
- 2017
- Full Text
- View/download PDF
159. Thrombin Generation Measurements in Patients Scheduled for Laparoscopic Bariatric Surgery.
- Author
-
Thereaux J, Mingant F, Roche C, Galinat H, Couturaud F, and Lacut K
- Subjects
- Adult, Biomarkers blood, Female, Humans, Laparoscopy, Male, Middle Aged, Obesity, Morbid complications, Prospective Studies, Risk Factors, Thrombin analysis, Thrombophilia diagnosis, Thrombophilia etiology, Bariatric Surgery, Blood Coagulation Tests, Obesity, Morbid blood, Thrombin metabolism, Thrombophilia blood
- Abstract
Purpose: Obese patients are known to be in an in vitro hypercoagulable state relative to normal-weight patients. Our study aimed to identify markers of enhanced coagulability (endogenous thrombin potential (ETP)) in morbidly obese patients using the thrombin generation (TG) test., Materials and Methods: All patients scheduled for laparoscopic bariatric surgery (LBS) between September 1, 2014 and January 31, 2016 were eligible for our prospective study. We used logistic regression to compute the odds ratio (OR) across ETP quartile distributions to evaluate the risk of enhanced TG., Results: We studied 102 patients, 77.5% were female, mean age was 41.2 ± 12.1 years, and mean BMI was 45.5 ± 7.0 k/m
2 . Total cholesterol and fibrinogen levels were found to be independent risk factors for patients in the 4th quartile distribution of the ETP distribution (OR (95% CI)) 2.6 (1.2 to 5.4) (P = 0.01) and 2.2 (1.1 to 4.5 (P = 0.03). Patients in the 4th quartile of the ETP distribution had a lower ETP 1 month after surgery (157 (144-196) vs. 120 (98-140); P < 0.001) in parallel with a trend toward lower total cholesterol levels (5.0 ± 0.9 vs. 4.4 ± 1.0; P = 0.06). Fibrinogen levels were stable (4.5 ± 1.0 vs. 4.4 ± 0.9); P = 0.7)., Conclusions: Our study highlights the role of total cholesterol and blood inflammatory marker levels in enhancing ETP in morbidly obese patients. Further studies are necessary to confirm the decreased ETP following LBS with the expected reduced inflammatory marker and total cholesterol levels.- Published
- 2017
- Full Text
- View/download PDF
160. Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study.
- Author
-
Le Mao R, Tromeur C, Bazire A, Gouillou M, Guegan M, Lacut K, Delluc A, Mottier D, Leroyer C, and Couturaud F
- Subjects
- Adult, Aged, Anticoagulants therapeutic use, Female, Follow-Up Studies, France epidemiology, Humans, Male, Middle Aged, Multivariate Analysis, Prospective Studies, Pulmonary Disease, Chronic Obstructive drug therapy, Pulmonary Disease, Chronic Obstructive mortality, Recurrence, Risk Assessment, Risk Factors, Survival Analysis, Venous Thromboembolism diagnosis, Withholding Treatment, Pulmonary Disease, Chronic Obstructive complications, Venous Thromboembolism epidemiology
- Abstract
We aimed to assess the risk of recurrent venous thromboembolism (VTE) in patients with chronic obstructive pulmonary disease (COPD) following cessation of anticoagulation therapy.In a prospective cohort of 1468 patients with a documented episode of VTE, followed for up to 5 years after cessation of anticoagulation therapy, the diagnosis of COPD was confirmed in 136. The main outcome was recurrent VTE. The secondary outcome was overall mortality. Univariate and multivariate analyses were performed to identify the risk factors of recurrence.Of the 1468 patients included, recurrent VTE was observed in 306 (34 with COPD and 272 without) during a median follow-up period of 36.5 months. The incidence rate of recurrent VTE was 9.1% (95% CI 6.5-12.8) for COPD patients and 7.0% (95% CI 6.2-7.9) for non-COPD patients. COPD was not associated with an increased risk of VTE recurrence on univariate or multivariate analyses (hazard ratio: 1.0 (95% CI 0.7-1.4)). The risk of death, adjusted for demographic and clinical characteristics, showed no increase in COPD patients, as compared to non-COPD patients.In patients with COPD who had an acute episode of VTE, the risk of recurrent VTE was not any higher than that in non-COPD patients., Competing Interests: Conflict of interest: None declared., (Copyright ©ERS 2017.)
- Published
- 2017
- Full Text
- View/download PDF
161. Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.
- Author
-
Robin P, Le Roux PY, Lacut K, Planquette B, Prévot-Bitot N, Lavigne C, Pastre J, Merah A, Le Gal G, and Salaun PY
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Neoplasms complications, Fluorodeoxyglucose F18 administration & dosage, Neoplasms diagnostic imaging, Positron-Emission Tomography methods, Tomography, X-Ray Computed methods, Venous Thromboembolism complications
- Abstract
Purpose: Small series have suggested that Fluorodesoxyglucose Positron-Emission-Tomography with Computed-Tomography (FDG-PET/CT) is feasible to screen for cancer in patients with unprovoked venous thromboembolism (VTE), but without validation in a large population. The aim was to assess diagnostic accuracy indices of FDG-PET/CT for occult cancer diagnosis in patients with unprovoked VTE., Materials and Methods: We analysed patients from the FDG-PET/CT group of a randomized trial that compared a screening strategy based on FDG-PET/CT with a limited screening strategy for occult malignancy detection in patients with unprovoked VTE. FDG-PET/CT was interpreted as positive for cancer, as negative or as equivocal. Patients were considered as having cancer on the basis of screening results, or of any test performed during a two-years follow-up period. We ran two sets of analysis, considering patients with equivocal FDG-PET/CT as positive, then as negative for malignancy., Results: Between March 2009, and August 2012, 172 patients were included. FDG-PET/CT was interpreted as positive for malignancy in 10 patients (5.8%), as equivocal in 23 patients (13.4%) and as negative in 139 patients (80.8%). Malignancy was diagnosed in 7/10 (70.0%), 2/23 (8.7%) and 1/139 (0.7%) patients, respectively. Grouping positive and equivocal results, sensitivity and specificity were 90% (95%CI 60% to 98%) and 85% (95%CI 79% to 90%), respectively. Grouping negative and equivocal results, sensitivity and specificity were 70% (95%CI 40% to 89%) and 98% (95%CI 95% to 99%), respectively., Conclusion: FDG-PET/CT showed good accuracy for occult cancer screening in patients with unprovoked VTE. Remaining challenges include the need to define specific interpretation criteria in this dedicated population.
- Published
- 2017
- Full Text
- View/download PDF
162. Reduction of coagulability state one year after bariatric surgery.
- Author
-
Thereaux J, Mingant F, Roche C, Galinat H, Couturaud F, and Lacut K
- Subjects
- Adult, Blood Coagulation Tests methods, C-Reactive Protein metabolism, Female, Fibrinogen metabolism, Gastrectomy methods, Gastric Bypass methods, Humans, Laparoscopy methods, Male, Obesity, Morbid blood, Postoperative Care, Prospective Studies, Thrombin metabolism, Thrombophilia blood, Thrombophilia surgery, Treatment Outcome, Weight Loss physiology, Bariatric Surgery methods, Obesity, Morbid surgery, Thrombophilia prevention & control
- Abstract
Background: Obese patients are in a hypercoagulable state relative to normal-weight patients. Low-grade inflammation may be a key factor for this condition., Objectives: Our study aimed to compare the coagulability state of morbidly obese patients before and 1 year after bariatric surgery (BS) using the Thrombin Generation (TG) test, a validated method to assess coagulation in vitro., Setting: University hospital., Methods: All patients undergoing BS between September 1, 2014 and April 30, 2015 were eligible for this prospective study (n = 42). Two distinct reagents were used for TG initiation based on the tissue factor concentration (Reagents LOW and HIGH). The main outcomes were endogenous thrombin potential (ETP) and peak height of TG. The rate of follow-up after one year was 97%., Results: One year after surgery, %weight loss was 32.5±8.4%; CRP decreased from 9.0 (3.7-12.9) to 1.1 (0.3-2.8) mg/mL (P<.001) and fibrinogen from 4.2±.8 to 3.5±.8 g/L (P<.001). The ETP (%) decreased from (108.0 (95.0-117.0) to 78.0 (71.0-98.0) (P<.001) (LOW reagent) and from 113.0 (103.0-134.0) to 96.0 (86.0-107.0) (P<.001) (HIGH reagent). Peak height (%) decreased from (117.0 (92.0-139.0) to 82.0 (70.0-111.0) (P = .003) (LOW reagent) and from 106.0 (96.0-118.0) to 97.0 (87.8-105.2) (P = .003) (HIGH reagent)., Conclusion: Our study shows a significant reduction in TG potential one year after BS in morbidly obese patients. Reduction of low grade inflammation may be one of the underlying mechanisms., (Copyright © 2017 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
163. External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis.
- Author
-
Astruc N, Ianotto JC, Metges JP, Lacut K, and Delluc A
- Subjects
- Aged, Breast Neoplasms epidemiology, Cohort Studies, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms epidemiology, Male, Neoplasm Staging, Recurrence, Reproducibility of Results, Risk Assessment, Risk Factors, Sex Factors, Decision Support Techniques, Neoplasms epidemiology, Pulmonary Embolism epidemiology, Venous Thromboembolism epidemiology, Venous Thrombosis epidemiology
- Published
- 2016
- Full Text
- View/download PDF
164. Variations of hepcidin and iron-status parameters during the menstrual cycle in healthy women.
- Author
-
Lainé F, Angeli A, Ropert M, Jezequel C, Bardou-Jacquet E, Deugnier Y, Gissot V, Lacut K, Sacher-Huvelin S, Lavenu A, Laviolle B, and Comets E
- Subjects
- Adolescent, Adult, Female, Healthy Volunteers, Humans, Middle Aged, Young Adult, Hepcidins metabolism, Iron metabolism, Menstrual Cycle metabolism
- Published
- 2016
- Full Text
- View/download PDF
165. Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France.
- Author
-
Delluc A, Tromeur C, Le Ven F, Gouillou M, Paleiron N, Bressollette L, Nonent M, Salaun PY, Lacut K, Leroyer C, Le Gal G, Couturaud F, and Mottier D
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, France epidemiology, Humans, Incidence, Infant, Infant, Newborn, Male, Middle Aged, Young Adult, Pulmonary Embolism epidemiology, Venous Thromboembolism epidemiology, Venous Thrombosis epidemiology
- Abstract
In 1998 we estimated the incidence of venous thromboembolism (VTE) to be 1.8/1,000 per year. The aim of this study was to compare current VTE incidence to that observed in 1998. We prospectively recorded all cases of symptomatic pulmonary embolism (PE) and deep vein thrombosis (DVT) of the lower limbs diagnosed between March 1, 2013 and February 28, 2014 in hospitals and in the community, using the same method and geographic area than in 1998. The 2013 incidence rates of VTE were computed and compared with those of 1998 using age- and sex-specific standardised incidence ratios (SIRs). In 2013, we recorded 576 VTE cases (279 isolated DVT and 297 PE ± DVT). Among 367,911 inhabitants, the overall incidence of VTE was 1.57/1,000 (95 % CI 1.44-1.69). The overall VTE incidence was significantly lower in 2013 as compared with 1998: SIR 0.72 (95 % CI 0.67-0.79) as well as the incidence of isolated DVT: SIR 0.53 (95 % CI 0.47-0.60); conversely, the overall incidence of PE was unchanged: SIR 1.10 (95 % CI, 0.98-1.23) despite an increase in the incidence of isolated PE: SIR 1.29 (95 % CI, 1.10-1.52). In 1998, 4.4 % of PE cases were diagnosed using CTPA as compared with 73.7 % in 2013 (p < 0.001). In conclusion, between 1998 and 2013, the incidence of symptomatic DVT decreased. Conversely, we found no similar reduction in the incidence of symptomatic PE; whether this is due to changes in diagnostic tests and algorithms in the management of suspected PE requires further investigations.
- Published
- 2016
- Full Text
- View/download PDF
166. Joint Model of Iron and Hepcidin During the Menstrual Cycle in Healthy Women.
- Author
-
Angeli A, Lainé F, Lavenu A, Ropert M, Lacut K, Gissot V, Sacher-Huvelin S, Jezequel C, Moignet A, Laviolle B, and Comets E
- Subjects
- Adult, Female, Healthy Volunteers, Humans, Young Adult, Anti-Infective Agents blood, Hepcidins blood, Iron blood, Menstrual Cycle blood, Models, Biological
- Abstract
Hepcidin regulates serum iron levels, and its dosage is used in differential diagnostic of iron-related pathologies. We used the data collected in the HEPMEN (named after HEPcidin during MENses) study to investigate the joint dynamics of serum hepcidin and iron during the menstrual cycle in healthy women. Ninety menstruating women were recruited after a screening visit. Six fasting blood samples for determination of iron-status variables were taken in the morning throughout the cycle, starting on the second day of the period. Non-linear mixed effect models were used to describe the evolution of iron and hepcidin. Demographic and medical covariates were tested for their effect on model parameters. Parameter estimation was performed using the SAEM algorithm implemented in the Monolix software. A general pattern was observed for both hepcidin and iron, consisting of an initial decrease during menstruation, followed by a rebound and stabilising during the second half of the cycle. We developed a joint model including a menstruation-induced decrease of both molecules at the beginning of the menses and a rebound effect after menses. Iron stimulated the release of hepcidin. Several covariates, including contraception, amount of blood loss and ferritin, were found to influence the parameters. The joint model of iron and hepcidin was able to describe the fluctuations induced by blood loss from menstruation in healthy non-menopausal women and the subsequent regulation. The HEPMEN study showed fluctuations of iron-status variables during the menstrual cycle, which should be considered when using hepcidin measurements for diagnostic purposes in women of child-bearing potential.
- Published
- 2016
- Full Text
- View/download PDF
167. Serum levels of 25(OH)D are not associated with venous thromboembolism in the elderly population. A case-control study.
- Author
-
Andro M, Delluc A, Moineau MP, Tromeur C, Gouillou M, Lacut K, Carré JL, Gentric A, and Le Gal G
- Subjects
- Age Factors, Aged, Aged, 80 and over, Biomarkers blood, Body Mass Index, Case-Control Studies, Chi-Square Distribution, Female, France epidemiology, Geriatric Assessment, Humans, Incidence, Independent Living, Logistic Models, Male, Multivariate Analysis, Obesity epidemiology, Odds Ratio, Prevalence, Prospective Studies, Risk Assessment, Risk Factors, Seasons, Time Factors, Venous Thromboembolism blood, Venous Thromboembolism diagnosis, Vitamin D blood, Vitamin D Deficiency blood, Vitamin D Deficiency diagnosis, Walking, Venous Thromboembolism epidemiology, Vitamin D analogs & derivatives, Vitamin D Deficiency epidemiology
- Abstract
The prevalence of both vitamin D deficiency and venous thromboembolism (VTE) is important in the elderly. Previous studies have provided evidence for a possible association between vitamin D status and the risk of VTE. Thus, we aimed to investigate the association between vitamin D levels and VTE in the population aged 75 and over included in the EDITH case-control study. The association between vitamin D status and VTE was analysed. We also analysed the monthly and seasonal variations of VTE and vitamin D. Between May 2000 and December 2009, 340 elderly patients (mean age 81.5 years, 32% men) with unprovoked VTE and their controls were included. The univariate and multivariate analysis found no significant association between serum levels of vitamin D and the risk of unprovoked VTE. In the unadjusted analysis, a higher BMI was statistically associated with an increased risk of VTE (OR 1.09; 95% CI 1.05-1.13) whereas a better walking capacity and living at home were associated with a decreased rate of VTE: OR 0.57; 95% CI 0.36-0.90 and 0.40; 95% CI 0.25-0.66, respectively. Although not significant, more VTE events occurred during winter (p=0.09). No seasonal variations of vitamin D levels were found (p=0.11). In conclusion, in contrast with previous reports our findings suggest that vitamin D is not associated with VTE in the elderly population.
- Published
- 2016
- Full Text
- View/download PDF
168. Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study.
- Author
-
Le Moigne E, Tromeur C, Delluc A, Gouillou M, Alavi Z, Lacut K, Mottier D, and Le Gal G
- Subjects
- Adult, Contraceptives, Oral, Hormonal administration & dosage, Female, Humans, Middle Aged, Progestins administration & dosage, Retrospective Studies, Risk Factors, Contraceptives, Oral, Hormonal adverse effects, Progestins adverse effects, Venous Thromboembolism chemically induced, Venous Thromboembolism epidemiology
- Published
- 2016
- Full Text
- View/download PDF
169. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
- Author
-
Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Guégan M, Bosson JL, Laporte S, Leroyer C, Décousus H, Meyer G, and Mottier D
- Subjects
- Adult, Aged, Anticoagulants adverse effects, Double-Blind Method, Drug Administration Schedule, Hemorrhage chemically induced, Humans, Middle Aged, Recurrence, Risk Factors, Secondary Prevention, Warfarin adverse effects, Anticoagulants administration & dosage, Pulmonary Embolism drug therapy, Venous Thromboembolism prevention & control, Warfarin administration & dosage
- Abstract
Importance: The optimal duration of anticoagulation after a first episode of unprovoked pulmonary embolism is uncertain., Objectives: To determine the benefits and harms of an additional 18-month treatment with warfarin vs placebo, after an initial 6-month nonrandomized treatment period on a vitamin K antagonist., Design, Setting, and Participants: Randomized, double-blind trial (treatment period, 18 months; median follow-up, 24 months); 371 adult patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist were randomized and followed up between July 2007 and September 2014 in 14 French centers., Interventions: Warfarin or placebo for 18 months., Main Outcomes and Measures: The primary outcome was the composite of recurrent venous thromboembolism or major bleeding at 18 months after randomization. Secondary outcomes were the composite at 42 months (treatment period plus 24-month follow-up), as well as each component of the composite, and death unrelated to pulmonary embolism or major bleeding, at 18 and 42 months., Results: After randomization, 4 patients were lost to follow-up, all after month 18, and 1 withdrew due to an adverse event. During the 18-month treatment period, the primary outcome occurred in 6 of 184 patients (3.3%) in the warfarin group and in 25 of 187 (13.5%) in the placebo group (hazard ratio [HR], 0.22; 95% CI, 0.09-0.55; P = .001). Recurrent venous thromboembolism occurred in 3 patients in the warfarin group and 25 patients in the placebo group (HR, 0.15; 95% CI, 0.05-0.43); major bleeding occurred in 4 patients in the warfarin group and in 1 patient in the placebo group (HR, 3.96; 95% CI, 0.44 to 35.89). During the 42-month entire study period (including the study treatment and follow-up periods), the composite outcome occurred in 33 patients (20.8%) in the warfarin group and in 42 (24.0%) in the placebo group (HR, 0.75; 95% CI, 0.47-1.18). Rates of recurrent venous thromboembolism, major bleeding, and unrelated death did not differ between groups., Conclusions and Relevance: Among patients with a first episode of unprovoked pulmonary embolism who received 6 months of anticoagulant treatment, an additional 18 months of treatment with warfarin reduced the composite outcome of recurrent venous thrombosis and major bleeding compared with placebo. However, benefit was not maintained after discontinuation of anticoagulation therapy., Trial Registration: clinicaltrials.gov Identifier: NCT00740883.
- Published
- 2015
- Full Text
- View/download PDF
170. A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone.
- Author
-
Moreau C, Pautas E, Duverlie C, Berndt C, Andro M, Mahé I, Emmerich J, Lacut K, Le Gal G, Peyron I, Gouin-Thibault I, Golmard JL, Loriot MA, and Siguret V
- Subjects
- Aged, Aged, 80 and over, Amiodarone therapeutic use, Female, Gene-Environment Interaction, Genotype, Heart Rate drug effects, Humans, Inactivation, Metabolic genetics, Male, Phenindione pharmacokinetics, Phenindione therapeutic use, Polymorphism, Genetic, Vascular Resistance drug effects, Vitamin K genetics, Body Weight, Drug Dosage Calculations, Models, Biological, Pharmacogenetics methods, Phenindione analogs & derivatives
- Abstract
Indandione VKAs have been widely used for decades, especially in Eastern Europe and France. Contrary to coumarin VKAs, the relative contribution of individual factors to the indandione-VKA response is poorly known. In the present multicentre study, we sought to develop and validate a model including genetic and non-genetic factors to predict the daily fluindione dose requirement in elderly patients in whom VKA dosing is challenging. We prospectively recorded clinical and therapeutic data in 230 Caucasian inpatients mean aged 85 ± 6 years, who had reached international normalized ratio stabilisation (range 2.0-3.0) on fluindione. In the derivation cohort (n=156), we analysed 13 polymorphisms in seven genes potentially involved in the pharmacological effect or vitamin-K cycle (VKORC1, CYP4F2, EPHX1) and fluindione metabolism/transport (CYP2C9, CYP2C19, CYP3A5, ABCB1). We built a regression model incorporating non-genetic and genetic data and evaluated the model performances in a separate cohort (n=74).Body-weight, amiodarone intake, VKORC1, CYP4F2, ABCB1 genotypes were retained in the final model, accounting for 31.5% of dose variability. None influence of CYP2C9 was observed. Our final model showed good performances: in 83.3% of the validation cohort patients, the dose was accurately predicted within 5 mg, i.e.the usual step used for adjusting fluindione dosage. In conclusion, in addition to body-weight and amiodarone-intake, pharmacogenetic factors (VKORC1, CYP4F2, ABCB1) related to the pharmacodynamic effect and transport of fluindione significantly influenced the dose requirement in elderly patients while CYP2C9 did not. Studies are required to know whether fluindione could be an alternative VKA in carriers of polymorphic CYP2C9 alleles, hypersensitive to coumarins.
- Published
- 2014
- Full Text
- View/download PDF
171. Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics.
- Author
-
Delluc A, Rousseau A, Le Galudec M, Canceil O, Woodhams B, Etienne S, Walter M, Mottier D, Van Dreden P, and Lacut K
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Antiphospholipid blood, Antipsychotic Agents therapeutic use, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Prevalence, Psychotic Disorders blood, Psychotic Disorders diagnosis, Psychotic Disorders drug therapy, Psychotic Disorders immunology, Young Adult, Antibodies, Antiphospholipid immunology, Antipsychotic Agents adverse effects, Seroepidemiologic Studies
- Abstract
Past reports have suggested that antiphospholipid (aPL) antibodies may emerge as a response to antipsychotics treatment, as a high prevalence of aPL antibodies in antipsychotics users has been observed. However, no control group of non-medicated psychiatric patients was included in these reports. In a cross sectional study we determined the prevalence of aPL antibodies in 333 psychiatric inpatients. We compared the proportions of positive aPL antibodytests between users and non-users of antipsychotics with adjustments for potential confounders. The proportion of antipsychotics users carrying at least one aPL antibody ranged from 10·8% to 27·0% compared with 6·8% to 27·2% in non-users (P = 0·24, P = 0·24) depending on the method of detection of lupus anticoagulant (LA). The prevalence of LA detected by dilute Russell viper venom time or partial thromboplastin time-LA was not different between antipsychotics users and non-users (8·1% vs. 5·4%, P = 0·53 and 18·4% vs. 18·2%, P = 0·22), as well as the prevalence of IgM and IgG anti-β2-glycoprotein-I antibodies, IgM and IgG anti-cardiolipin antibodies(3·8% vs. 2·0%, P = 0·75, 0·0% vs. 0·0%, P = not applicable, 1·1 vs. 1·4%, P = 0·91, 2·7% vs. 3·4%, P = 0·71). In conclusion, aPL antibodies were frequently found in patients with psychiatric diseases and no significant increase in the prevalence of aPL antibodies was observed in antipsychotics users., (© 2013 John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
172. Body mass index, a major confounder to insulin resistance association with unprovoked venous thromboembolism. Results from the EDITH case-control study.
- Author
-
Delluc A, De Moreuil C, Kerspern H, Le Moigne E, Mottier D, Tromeur C, Carre JL, Le Gal G, and Lacut K
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Hyperglycemia complications, Male, Middle Aged, Odds Ratio, Risk Factors, Young Adult, Body Mass Index, Insulin Resistance, Obesity complications, Venous Thromboembolism complications
- Abstract
Shared risk factors help explain the association between venous thromboembolism (VTE) and atherothrombosis. The potential association between insulin resistance and VTE has been poorly evaluated. Thus, we aimed to assess the association between insulin resistance and VTE in the EDITH hospital-based case-control study. Between May 2000 and December 2004, 677 patients with unprovoked VTE and their age- and sex-matched controls were included. Fasting glycaemia and insulinaemia were measured and insulin resistance was estimated with the homeostasis model assessment of insulin resistance (HOMA-IR) equation. The association between HOMA-IR and VTE was determined in non-diabetic patients in a quintile-based analysis. A total of 590 non-diabetic cases (median age 73.0 years, 255 men) and 581 non-diabetic controls (median age 72.0 years, 247 men) were analysed. There was a trend for a higher median level of HOMA-IR index in cases than in controls (1.21 [interquartile range 0.84-2.10] vs1.19 [interquartile range 0.72-2.02], p=0.08). The unadjusted analysis showed an increased risk of unprovoked VTE associated with increasing HOMA-IR (odds ratio [OR] 1.53; 95% confidence interval [CI] 1.00-2.34 for the highest quintile of HOMA-IR compared with the first quintile). Adjustment for lipid lowering drugs and antiplatelet agents use slightly modified the association (OR 1.51; 95% CI 0.97-2.34). When body mass index was added in the adjusted model, HOMA-IR was no longer associated with VTE (OR 1.08; 95% CI 0.67-1.73). Our results highlight the role of body mass index in the association between cardiovascular risk factors and VTE.
- Published
- 2013
- Full Text
- View/download PDF
173. Risk of recurrent venous thromboembolism among young women after a first event while exposed to combined oral contraception versus not exposed to: a cohort study.
- Author
-
Le Moigne E, Delluc A, Tromeur C, Nowak E, Mottier D, Lacut K, and Le Gal G
- Subjects
- Adult, Cohort Studies, Female, Humans, Incidence, Recurrence, Risk Factors, Young Adult, Anticoagulants therapeutic use, Contraceptives, Oral, Combined adverse effects, Venous Thromboembolism epidemiology, Venous Thromboembolism prevention & control
- Abstract
The risk of recurrent venous thromboembolism (VTE) in young women after a first oestrogen contraception associated VTE episode is unknown. This uncertainty has an impact on the decision whether to stop anticoagulant treatment. Our objective was to assess the risk of recurrent VTE in women after a first VTE episode on oestrogen contraception. This was a prospective cohort study in which we consecutively enrolled between 1992 and 2011 all women under 50years with a first objectively confirmed VTE. The incidence of recurrent VTE during follow-up after stopping anticoagulation was compared between women users and non-users of combined oral contraception (COC) at the time of index VTE. Of the 241 women aged 50 or younger seen for a first VTE and followed-up after stopping anticoagulation, there were 180 COC-users and 61 non-users. Median duration of follow-up off-anticoagulants was 66 months (interquartile range: 33-103). There were 14 recurrences in COC-users and 5 cases in non-users. No significant association was found between exposure to COC and the incidence of recurrent VTE after adjustment for age or after restricting the analysis to major unprovoked VTE: incidence rate of recurrence 17.9/1,000/year (95% CI: 9.6-33.2) in women with COC as compared with 17.6/1,000/year (95% CI: 6.6-47) with an incidence ratio of 0.7 (95% CI: 0.2-2.4, p=0.59). The risk of recurrent VTE is low in young women after a first VTE. However, this risk is not significantly lower in women after a first VTE while exposed to combined oral contraception., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
174. Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: the CIREA1 randomized trial.
- Author
-
Vignon P, Dequin PF, Renault A, Mathonnet A, Paleiron N, Imbert A, Chatellier D, Gissot V, Lhéritier G, Aboyans V, Prat G, Garot D, Boulain T, Diehl JL, Bressollette L, Delluc A, and Lacut K
- Subjects
- Female, Hemorrhage complications, Humans, Intensive Care Units, Male, Middle Aged, Risk Factors, Treatment Outcome, Ultrasonography, Venous Thromboembolism diagnostic imaging, Intermittent Pneumatic Compression Devices, Stockings, Compression, Venous Thromboembolism prevention & control
- Abstract
Purpose: Venous thromboembolism (VTE) is a frequent and serious problem in intensive care units (ICU). Anticoagulant treatments have demonstrated their efficacy in preventing VTE. However, when the bleeding risk is high, they are contraindicated, and mechanical devices are recommended. To date, mechanical prophylaxis has not been rigorously evaluated in any trials in ICU patients., Methods: In this multicenter, open-label, randomized trial with blinded evaluation of endpoints, we randomly assigned 407 patients with a high risk of bleeding to receive intermittent pneumatic compression (IPC) associated with graduated compression stockings (GCS) or GCS alone for 6 days during their ICU stay. The primary endpoint was the occurrence of a VTE between days 1 and 6, including nonfatal symptomatic documented VTE, or death due to a pulmonary embolism, or asymptomatic deep vein thrombosis detected by ultrasonography systematically performed on day 6., Results: The primary outcome was assessed in 363 patients (89.2%). By day 6, the incidence of the primary outcome was 5.6% (10 of 179 patients) in the IPC + GCS group and 9.2% (17 of 184 patients) in the GCS group (relative risk 0.60; 95% confidence interval 0.28-1.28; p = 0.19). Tolerance of IPC was poor in only 12 patients (6.0%). No intergroup difference in mortality rate was observed., Conclusions: With the limitation of a low statistical power, our results do not support the superiority of the combination of IPC + GCS compared to GCS alone to prevent VTE in ICU patients at high risk of bleeding.
- Published
- 2013
- Full Text
- View/download PDF
175. [Aspirin for secondary prevention of venous thromboembolism. WARFASA: far from being conclusive].
- Author
-
Delluc A, Lacut K, and Mottier D
- Subjects
- Anticoagulants adverse effects, Aspirin administration & dosage, Aspirin adverse effects, Hemorrhage epidemiology, Hemorrhage etiology, Hemorrhage prevention & control, Humans, Pulmonary Embolism chemically induced, Pulmonary Embolism epidemiology, Pulmonary Embolism etiology, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Secondary Prevention methods, Venous Thromboembolism complications, Venous Thromboembolism drug therapy, Venous Thromboembolism epidemiology, Warfarin administration & dosage, Warfarin adverse effects, Warfarin therapeutic use, Anticoagulants therapeutic use, Aspirin therapeutic use, Venous Thromboembolism prevention & control
- Published
- 2013
- Full Text
- View/download PDF
176. Incidence of venous thromboembolism in psychiatric units.
- Author
-
Delluc A, Montavon S, Canceil O, Carpentier M, Nowak E, Mercier B, Bressollette L, Etienne S, Walter M, Mottier D, and Lacut K
- Subjects
- Adult, Aged, Cohort Studies, Female, France epidemiology, Hospitalization, Humans, Incidence, Male, Middle Aged, Prospective Studies, Psychiatric Department, Hospital statistics & numerical data, Risk Factors, Mental Disorders blood, Mental Disorders epidemiology, Venous Thromboembolism epidemiology, Venous Thromboembolism psychology
- Abstract
Introduction: Incidence and risk factors of venous thromboembolism (VTE) are well established in surgical and medical settings, but data in psychiatric units are lacking. The aim of this study was to estimate the incidence of VTE in hospitalized psychiatric patients, and to assess the risk factors for VTE in this specific population., Materials and Methods: All consecutive adult patients, admitted for a psychiatric disorder for at least seven days in psychiatric units were considered for inclusion. Patients were evaluated for signs and symptoms of VTE during hospitalization. At Day 10, all participants were interviewed and a systematic compression ultrasonography of the lower limbs was performed. Patients were followed-up until Day 90., Results: Among the 471 included patients, 449 were evaluable at Day 10, and 458 were followed-up until Day 90. Ten deep vein thromboses (DVT) were diagnosed by Day 10 leading to an incidence of VTE of 2.2% (95% CI, 1.1%-4.1%). Six additional symptomatic VTE occurred between Day 10 and Day 90, leading to a 3.5% incidence at Day 90 (95% CI, 2.0%-5.6%). The main factors associated with VTE were age, bed rest, and diagnosis of dementia. The incidence of VTE in patients aged 75 or over with a diagnosis of dementia reached 8.2% at Day 10 and 12.5% at Day 90., Conclusions: The incidence of VTE in psychiatric units appeared low. However, in older patients, especially those with dementia, the incidence of VTE increased considerably. Further studies are needed to confirm these results., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
177. Lipid lowering drugs and the risk of recurrent venous thromboembolism.
- Author
-
Delluc A, Tromeur C, Le Moigne E, Nowak E, Mottier D, Le Gal G, and Lacut K
- Subjects
- Aged, Cohort Studies, Female, Fibric Acids therapeutic use, Humans, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Risk Factors, Secondary Prevention, Anticoagulants administration & dosage, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypolipidemic Agents therapeutic use, Venous Thromboembolism drug therapy, Venous Thromboembolism prevention & control
- Abstract
Introduction: Several studies have suggested that statins may lower the risk of venous thromboembolism (VTE), whereas fibrates may increase this risk. However, no studies have evaluated whether lipid-lowering drugs (LLD) use was associated with the risk of VTE recurrence., Materials and Methods: In a prospective cohort study, we followed-up all patients who had been treated for a first unprovoked VTE event in our centre. The association between LLD exposure and risk of recurrence of VTE after discontinuation of anticoagulation was analyzed with Cox proportional hazards model with adjustment for age, sex, body mass index, site of thrombosis, antiplatelets use, and duration of anticoagulation before inclusion in the study., Results: 432 patients (median age 65.5 years interquartile range 45.0-75.0, 174 men) were followed up for a median of 29.5 months after discontinuation of anticoagulation. Sixty patients (13.9%) had recurrent VTE. During follow-up, 48 patients (11.1%) received statins, 36 patients (8.3%) received fibrates. In multivariate analysis, the risk of recurrent VTE associated with statin exposure was 1.02 (95% confidence interval 0.36-2.91) and 2.15 (95% confidence interval 1.01-4.61) for fibrate exposure., Conclusion: Our results suggest an association between fibrate intake and an increased risk of recurrent VTE, whereas statin intake was not associated with recurrent VTE. Larger studies are needed to validate these results., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
178. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
- Author
-
Lacut K, Ayme-Dietrich E, Gourhant L, Poulhazan E, Andro M, Becquemont L, Mottier D, Le Gal G, and Verstuyft C
- Subjects
- Aged, Aged, 80 and over, Blood Coagulation genetics, Case-Control Studies, Cytochrome P-450 CYP2C9, Cytochrome P450 Family 4, Dose-Response Relationship, Drug, Female, Genotype, Humans, International Normalized Ratio, Male, Middle Aged, Pharmacogenetics, Phenindione pharmacology, Polymorphism, Genetic drug effects, Time Factors, Vitamin K Epoxide Reductases, Anticoagulants pharmacology, Aryl Hydrocarbon Hydroxylases genetics, Blood Coagulation drug effects, Cytochrome P-450 Enzyme System genetics, Epoxide Hydrolases genetics, Mixed Function Oxygenases genetics, Phenindione analogs & derivatives
- Abstract
Aim: Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9) and of a key pharmacologic target of vitamin K antagonists, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to coumarin derivatives. The role of these variants in fluindione response is unknown. Our aim was to assess whether genetic factors contribute to the variability in the response to fluindione., Methods: Four hundred sixty-five patients with a venous thromboembolic event treated by fluindione for at least 3 months with a target international normalized ratio (INR) of 2.0 to 3.0 were studied. VKORC1, CYP2C9, CYP4F2 and EPHX1 genotypes were assessed. INR checks, fluindione doses and bleeding events were collected., Results: VKORC1 genotype had a significant impact on early anticoagulation (INR value ≥2 after the first two intakes) (P < 0.0001), on the time required to reach a first INR within the therapeutic range (P < 0.0001) and on the time to obtain a first INR value > 4 (P= 0.0002). The average daily dose of fluindione during the first period of stability was significantly associated with the VKORC1 genotype: 19.8 mg (±5.5) for VKORC1 CC, 14.7mg (±6.2) for VKORC1 CT and 8.2mg (±2.5) for VKORC1 TT (P < 0.0001). CYP2C9, CYP4F2 and EPHX1 genotypes did not significantly influence the response to fluindione., Conclusions: VKORC1 genotype strongly affected anticoagulation induced by fluindione whereas CYP2C9, CYP4F2 and EPHX1 genotypes seemed less determining., (© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.)
- Published
- 2012
- Full Text
- View/download PDF
179. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.
- Author
-
Delluc A, Malécot JM, Kerspern H, Nowak E, Carre JL, Mottier D, Le Gal G, and Lacut K
- Subjects
- Aged, Aged, 80 and over, Apolipoprotein A-I blood, Apolipoproteins B blood, Atherosclerosis blood, Biomarkers blood, Case-Control Studies, Chi-Square Distribution, Cholesterol blood, Cholesterol, HDL blood, Cholesterol, LDL blood, Dyslipidemias blood, Female, France, Hospitals, University, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Prospective Studies, Risk Assessment, Risk Factors, Sex Factors, Time Factors, Treatment Outcome, Triglycerides blood, Venous Thromboembolism blood, Atherosclerosis complications, Atherosclerosis drug therapy, Dyslipidemias complications, Dyslipidemias drug therapy, Fibric Acids therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Lipids blood, Venous Thromboembolism etiology
- Abstract
Background: Besides their effects on atherogenesis, lipids and lipoproteins could contribute to the development of venous thromboembolism (VTE). This association has been investigated in a few studies with conflicting results., Methods: Plasma levels of total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, apolipoprotein A-I and apolipoprotein B were measured in 467 patients with a first unprovoked VTE event diagnosed between May 2000 and December 2004 and in 467 age and sex matched controls. The association between these parameters and VTE was determined in non-users of lipid lowering drugs (LLD), in statin users and in fibrate users in a quartile-based analysis. We repeated this stratified analysis within each stratum of men and women., Results: The median age of patients was 73 years [interquartile range 58-80], 41.5% were men. Among the 934 patients of the study, 100 were treated with statin, 91 with fibrate and 743 were not receiving LLD. Among non users of LLD, high levels of apolipoprotein B were associated with VTE (OR 1.82, 95% CI 1.19-2.79) after adjustment for age and body mass index. Elevated LDL-cholesterol levels were associated with VTE only in men (OR 2.32, 95% CI 1.07-5.01). High levels of LDL/HDL-cholesterol and apolipoprotein B/apolipoprotein A-I ratios were associated with VTE (OR 2.76, 95% CI 1.69-4.50 and OR 1.86, 95% CI 1.16-2.97 respectively) but this effect was mainly observed in men. There was no association between lipid parameters and VTE in statin users and in fibrate users., Conclusion: Our results are in line with the new concept of a global cardiovascular disease combining atherosclerosis and VTE., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
180. [Mechanical prophylaxis of venous thromboembolism].
- Author
-
Lacut K
- Subjects
- Compression Bandages, Humans, Venous Thromboembolism prevention & control
- Abstract
Mechanical devices for the prevention of venous thromboembolism (VTE) act on venous stasis and include static systems: the graduated compression stockings (or elastic stockings or anti-embolism stockings) and dynamical systems: intermittent pneumatic compression and venous foot pump. The main advantage of these devices is that they have no risk of bleeding. If the prevention of VTE is based primarily on drug prophylaxis, mechanical devices are recommended primarily for patients with high risk of bleeding, if there is contraindication to anticoagulants. Alone or in combination with drug prophylaxis, their efficacy on deep vein thrombosis prevention is well documented in surgery, but the evidence is insufficient for the prevention of pulmonary embolism and in other settings. Their interest in stroke is called into question after the results of the CLOTS 1 and 2 studies. These results, beyond the context of stroke, have raised numerous questions about the real benefit/risk ratio of mechanical devices for the prevention of VTE. They highlight the need to assess or re-evaluate mechanical devices by rigorous clinical trials.
- Published
- 2011
181. Site of venous thromboembolism and prothrombotic mutations according to body mass index. Results from the EDITH study.
- Author
-
Delluc A, Le Moigne E, Tromeur C, Noel-Savina E, Couturaud F, Mottier D, Le Gal G, and Lacut K
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Body Mass Index, Epidemiologic Methods, Factor V genetics, Female, France epidemiology, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Obesity epidemiology, Obesity physiopathology, Pulmonary Embolism epidemiology, Pulmonary Embolism etiology, Pulmonary Embolism genetics, Venous Thromboembolism epidemiology, Venous Thromboembolism genetics, Young Adult, Mutation, Obesity complications, Prothrombin genetics, Venous Thromboembolism etiology
- Abstract
This study evaluated the impact of body mass index (BMI) on venous thromboembolism (VTE) site and assessed a possible interaction between BMI and prothrombotic risk factors in patients included in the EDITH (Etude des Déterminants et Interactions de le THrombose veineuse) study. A cross-sectional study was used to compare the site of unprovoked VTE according to BMI categories in 1077 patients and a matched case-control study (732 pairs) assessed the joint effect of BMI and prothrombotic mutations on VTE risk. The cross sectional analysis showed that the proportion of patients with pulmonary embolism was higher in overweight (63%) and obese (63·5%) patients than among patients with a BMI<25kg/m(2) (55%), P=0·02 and P=0·05 respectively. No interaction was found between F5 G1691A (factor V Leiden) and BMI for VTE risk (P=0·90). There was a significant interaction between F2 G20210A and BMI (P=0·02). The risk of VTE associated with BMI was 1·7 [95% confidence interval (CI): 0·8-3·7], 4·36 (95%CI: 1·49-12·78) and 12·03 (95%CI: 1·53-94·29) in patients with BMI<25kg/m(2) , 25≤BMI<30 and ≥30kg/m(2) respectively after adjustment for age and oestrogen use. This study showed that BMI may play a role in determining the site of VTE and may interact with F2 G20210A but not with F5 G1691A for the risk of VTE., (© 2011 Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
182. Noninvasive diagnosis of pulmonary embolism.
- Author
-
Salaun PY, Couturaud F, Le Duc-Pennec A, Lacut K, Le Roux PY, Guillo P, Pennec PY, Cornily JC, Leroyer C, and Le Gal G
- Subjects
- Aged, Aged, 80 and over, Algorithms, Angiography, Cohort Studies, Enzyme-Linked Immunosorbent Assay, Fibrin Fibrinogen Degradation Products metabolism, Humans, Middle Aged, Perfusion Imaging, Prognosis, Pulmonary Embolism blood, Pulmonary Embolism therapy, Tomography, X-Ray Computed, Ventilation-Perfusion Ratio, Pulmonary Embolism diagnosis
- Abstract
Background: We designed a simple and integrated diagnostic algorithm for acute pulmonary embolism (PE). Diagnosis was based on clinical probability assessment, plasma D-dimer testing, then sequential testing to include lower limb venous compression ultrasonography, ventilation perfusion lung scan, and chest multidetector CT (MDCT) imaging., Methods: We included 321 consecutive patients presenting at Brest University Hospital in Brest, France, with clinically suspected PE and positive d-dimer or high clinical probability. Patients in whom VTE was deemed absent were not given anticoagulants and were followed up for 3 months., Results: Detection of DVT by ultrasonography established the diagnosis of PE in 43 (13%). Lung scan associated with clinical probability was diagnostic in 243 (76%) of the remaining patients. MDCT scan was required in only 35 (11%) of the patients. The 3-month thromboembolic risk in patients not given anticoagulants, based on the results of the diagnostic protocol, was 0.53% (95% CI, 0.09-2.94)., Conclusions: A diagnostic strategy combining clinical assessment, d-dimer, ultrasonography, and lung scan gave a noninvasive diagnosis in the majority of outpatients with suspected PE and appeared to be safe.
- Published
- 2011
- Full Text
- View/download PDF
183. Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor.
- Author
-
Delluc A, Rousseau A, Delluc C, Le Moigne E, Le Gal G, Mottier D, Van Dreden P, and Lacut K
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Fibrin Fibrinogen Degradation Products analysis, Humans, Incidence, Male, Middle Aged, Neoplasm Staging, Neoplasms epidemiology, Neoplasms physiopathology, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms physiopathology, Prospective Studies, Thromboplastin biosynthesis, Venous Thromboembolism epidemiology, Venous Thromboembolism physiopathology, Neoplasms blood, Pancreatic Neoplasms blood, Pancreatic Neoplasms complications, Thromboplastin analysis, Venous Thromboembolism blood, Venous Thromboembolism complications
- Abstract
Among cancers, pancreatic cancer is known to be associated with a higher incidence of venous thromboembolism (VTE). The aim of the study was to determine the implication of circulating tissue factor (TF) in VTE related to active pancreatic cancer. One hundred and sixty-four consecutive patients who participated to the Etude des Determinants et Interactions de la Thrombose veineuse (EDITH) study between January 2005 and August 2007 for symptomatic VTE related to active pancreatic cancer (n = 8), active cancer of other location (n = 42) or classified as unprovoked (n = 114) were included. TF activity (TFa) was measured in a one-stage kinetic chromogenic method. There were no differences of median TFa levels between patients with VTE related to cancer of other type than pancreas [2.01 pmol/l range (0.05-43.92)] and patients with unprovoked VTE [1.78 pmol/l (range 0.05-63.72), P = 0.21]. Median TFa levels were higher in patients with VTE related to pancreatic cancer [12.67 pmol/l (range 0.05-112.04)] than in patients with VTE related to cancer of other type [2.01 pmol/l (range 0.05-43.92), P = 0.02]. Higher levels of circulating TFa during the course of pancreatic cancer may explain the higher incidence of VTE associated with this type of cancer.
- Published
- 2011
- Full Text
- View/download PDF
184. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study.
- Author
-
Le Gal G, Kovacs MJ, Carrier M, Do K, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Righini M, Lacut K, White RH, Vickars L, and Rodger M
- Subjects
- Adolescent, Adult, Aged, Canada, Europe, Female, Humans, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Recurrence, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, United States, Venous Thromboembolism chemically induced, Young Adult, Anticoagulants therapeutic use, Contraceptives, Oral, Hormonal adverse effects, Estrogen Replacement Therapy adverse effects, Venous Thromboembolism drug therapy
- Abstract
The use of exogenous oestrogen in women with otherwise unprovoked venous thromboembolism (VTE) could be considered sufficient explanation to classify VTE as provoked if the risk of recurrent VTE after 3-6 months of anticoagulant treatment is similar to the risk of recurrent VTE observed after a surgery or prolonged immobilisation. Our objective was to assess the risk of recurrent VTE in women after a first unprovoked episode on oestrogen. The REVERSE study is a cohort study of patients with a first unprovoked VTE treated with anticoagulant treatment for 5-7 months. The risk of recurrent VTE during follow-up was compared between women users and non users of oestrogen at the time of index VTE. Among the 646 patients included, 314 were women, of them 67 were current users of oestrogen at the time of their VTE: 49 were on oral contraceptives and 18 on post-menopausal hormone replacement therapy (HRT). No significant association was found between oestrogen exposure, either oral contraceptives or HRT, and a lower risk of recurrent VTE after adjustment for age, or analysis restricted to women in the same age range as oestrogen contraceptives and HRT users, respectively. The risk of recurrent VTE is low in women after a first otherwise unprovoked oestrogen-associated VTE. However, this risk is not significantly lower than in women whose VTE was not related to oestrogen use.
- Published
- 2010
- Full Text
- View/download PDF
185. Serum lipoprotein (a) levels in patients with first unprovoked venous thromboembolism is not associated with subsequent risk of recurrent VTE.
- Author
-
Rodger MA, Le Gal G, Carrier M, Betancourt MT, Kahn SR, Wells PS, Anderson DA, Lacut K, Chagnon I, Solymoss S, Crowther M, Perrier A, White R, Vickars L, Ramsay T, and Kovacs MJ
- Subjects
- Adult, Aged, Biomarkers blood, Canada, Chi-Square Distribution, Drug Administration Schedule, Europe, Female, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Odds Ratio, Prospective Studies, Recurrence, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Up-Regulation, Venous Thromboembolism mortality, Anticoagulants administration & dosage, Lipoprotein(a) blood, Venous Thromboembolism blood, Venous Thromboembolism drug therapy
- Abstract
Introduction: Case-control studies suggest that elevated lipoprotein (a) (Lp(a)) is a risk factor for first venous thromboembolism (VTE). Lp(a) has not been prospectively investigated as a possible risk factor for recurrent VTE in first unprovoked VTE patients. We sought to determine if serum Lp(a) levels in patients with unprovoked VTE who discontinue anticoagulants after 5 to 7 months of therapy predict VTE recurrence in a prospective cohort study., Materials and Methods: Serum Lp(a) measurements were obtained from 510 first unprovoked VTE patients treated for 5 -7 months with anticoagulants in a 12 center study. Patients were subsequently followed for a mean of 16.9 months (SD+/-11.2) for symptomatic VTE recurrence which was independently adjudicated with reference to baseline imaging., Results: There was no significant association between Lp(a) as a continuous variable and recurrent VTE nor in gender stratified subgroups. No statistically significant differences were observed in the median Lp(a) concentrations between patients who recurred and those who did not recur (median (interquartile range): 0.09 g/L (0.17) versus 0.06 g/L (0.11) respectively; p=0.15). The Lp(a) cut-off point of 0.3g/L was not significantly associated with recurrent VTE for the overall population nor in gender stratified subgroups., Conclusions: Elevated serum Lp(a) does not appear to be associated with recurrent VTE in patients with history of first unprovoked VTE and may not play a role in identifying patients with unprovoked VTE at high risk of recurrence. There was no optimal predictive threshold for the overall population or for sex sub-groups and Lp(a)>or=0.3 g/L was not a significant predictor of recurrent VTE., (Copyright (c) 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
186. Association of common genetic variations and idiopathic venous thromboembolism. Results from EDITh, a hospital-based case-control study.
- Author
-
Delluc A, Gourhant L, Lacut K, Mercier B, Audrezet MP, Nowak E, Oger E, Leroyer C, Mottier D, Le Gal G, and Couturaud F
- Subjects
- Aged, Blood Coagulation genetics, Case-Control Studies, Factor V genetics, Female, Gene Frequency, Genetic Association Studies, Genotype, Hospitals, Humans, Lipid Metabolism genetics, Male, Middle Aged, Platelet Aggregation genetics, Polymorphism, Single Nucleotide, Receptors, Adrenergic metabolism, Renin-Angiotensin System genetics, Venous Thromboembolism physiopathology, Factor XI genetics, Prothrombin genetics, Venous Thromboembolism genetics
- Abstract
Venous thromboembolism (VTE) is a multifactorial disease, caused by interacting environmental and genetic risk factors. Gene-centric genotyping strategy is one of the approaches to explore unexplained associations between risk factors and VTE. It was the objective of this study to evaluate, using a gene-centric genotyping strategy, polymorphisms in genes involved in the following pathways: coagulation cascade process, renin-angiotensin or adrenergic systems, lipid metabolism, platelet aggregation. Allele frequency was compared between 677 cases with idiopathic VTE and their matched controls. After Bonferroni adjustment, four single nucleotide polymorphisms (SNPs) were significantly associated with VTE: Factor XI rs925451 polymorphism, factor XI rs2289252 polymorphism, factor II rs1799963 (G20210A) polymorphism and factor V Leiden rs6025. An additive mode of inheritance fitted best both factor XI polymorphisms. In this hospital-based case-control study, two polymorphisms located on the factor XI gene were significantly associated with VTE. Other newly investigated polymorphisms with potentially false negatives may warrant further analyses.
- Published
- 2010
- Full Text
- View/download PDF
187. Antihypertensive drugs and risk of venous thromboembolism: results from the EDITH case-control study.
- Author
-
Belattar FZ, Delluc A, Le Gal G, Leroyer C, Mottier D, Oger E, and Lacut K
- Subjects
- Aged, Aged, 80 and over, Angiotensin II Type 1 Receptor Blockers pharmacology, Case-Control Studies, Female, Humans, Hypertension complications, Hypertension drug therapy, Male, Middle Aged, Odds Ratio, Risk Factors, Surveys and Questionnaires, Venous Thromboembolism etiology, Antihypertensive Agents pharmacology, Blood Pressure drug effects, Venous Thromboembolism prevention & control
- Abstract
Previous studies evaluating the association between arterial blood pressure and venous thromboembolism (VTE) reported conflicting results. The relationship between antihypertensive therapy and VTE has never been specifically evaluated. This report from a hospital-based case-control study included 785 cases with confirmed unprovoked VTE and their 785 age- and sex-matched controls. Cases and controls were asked for drug exposure in a one-to-one standardized interview using the same questionnaire. Drug exposure was defined as current use of drugs at admission with onset at least 1 week ago. Three hundred and eighty-four out of 785 cases (48.9%) and 379 out 785 controls (48.3%) reported that they were currently using at least one antihypertensive drug. Among all antihypertensive therapies, only angiotensin II receptor blockers were significantly associated with a reduced risk for VTE: adjusted conditional odds ratio (OR) 0.45 (95% CI, 0.29-0.70). In this hospital-based case-control study, a preventive role for angiotensin II receptor blockers as regards VTE risk was suggested. More studies are needed in order to further elucidate the biological mechanisms involved.
- Published
- 2010
- Full Text
- View/download PDF
188. Effect of two oral doses of 17beta-estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double-blind placebo-controlled study.
- Author
-
Rousseau A, Robert A, Gerotziafas G, Torchin D, Zannad F, Lacut K, Libersa C, Dasque E, Démolis JL, Elalamy I, and Simon T
- Subjects
- Administration, Oral, Aged, Blood Coagulation Factors drug effects, Blood Coagulation Factors metabolism, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Dydrogesterone administration & dosage, Estradiol administration & dosage, Estrogens administration & dosage, Estrogens pharmacology, Female, Humans, Middle Aged, Progestins administration & dosage, Progestins pharmacology, Thrombin metabolism, Time Factors, Dydrogesterone pharmacology, Estradiol pharmacology, Menopause, Thrombin drug effects
- Abstract
Oral hormone therapy is associated with an increased risk of venous thrombosis. Drug agencies recommend the use of the lowest efficient dose to treat menopausal symptoms for a better risk/ratio profile, although this profile has not been totally investigated yet. The aim of the study was to compare the effect of the standard dose of 17beta-estradiol to a lower one on thrombin generation (TG). In a 2-month study, healthy menopausal women were randomized to receive daily 1mg or 2 mg of 17beta-estradiol (E1, n = 24 and E2, n = 26; respectively) with 10 mg dydrogesterone or placebo (PL, n = 22). Plasma levels factors VII, X, VIII and II were assessed before and after treatment as well as Tissue factor triggered TG, which allows the investigation of the different phases of coagulation process. The peak of thrombin was higher in hormone therapy groups (E1: 42.39 +/- 50.23 nm, E2: 31.08 +/- 85.86 nm vs. 10.52 +/- 40.63 nm in PL, P = 0.002 and P = 0.01). Time to reach the peak was also shortened (PL: 0.26 +/- 0.69 min vs. E1: -0.26 +/- 0.80 min, E2: -0.55 +/- 0.79 min, P <10(-3) for both comparisons) and mean rate index of the propagation phase of TG was significantly increased. Among the studied clotting factors, only the levels of FVII were significantly increased after treatment administration. The two doses of 17beta-estradiol induced in a similar degree an acceleration of the initiation and propagation phase of tissue factor triggered thrombin generation and a significant increase of FVII coagulant activity.
- Published
- 2010
- Full Text
- View/download PDF
189. Underweight is associated with a reduced risk of venous thromboembolism. Results from the EDITH case-control study.
- Author
-
Delluc A, Mottier D, Le Gal G, Oger E, and Lacut K
- Subjects
- Aged, Aged, 80 and over, Case-Control Studies, Female, Heart Failure, Humans, Male, Middle Aged, Prognosis, Venous Thromboembolism mortality, Thinness, Venous Thromboembolism etiology
- Published
- 2009
- Full Text
- View/download PDF
190. [Drugs and venous thromboembolism].
- Author
-
Lacut K, Mottier D, and Pottier P
- Subjects
- Angiogenesis Inhibitors adverse effects, Aspirin adverse effects, Estrogen Replacement Therapy adverse effects, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Platelet Aggregation Inhibitors adverse effects, Psychotropic Drugs adverse effects, Thalidomide adverse effects, Venous Thromboembolism chemically induced
- Abstract
Among the many factors likely to favour the occurrence of venous thromboembolism (VTE), exposure to certain drugs has to be taken into account. Although hormone treatments, oral contraception and hormone replacement therapy (HRT) for menopause have been studied, these are not the only drugs associated with an increased risk of VTE. The antipsychotics have also been incriminated in the occurrence of venous thromboembolism. The association of thalidomide and dexamethasone, used in the treatment of multiple myeloma, is responsible for a major increase in the risk of VTE. The physiopathological mechanisms accounting for the possible prothrombotic effect of most of these drugs is still not fully understood. Further observational and interventional clinical studies should provide a better understanding of VTE, potentially associated with drugs. However, certain drugs may be associated with a reduced risk of VTE. Although several studies indicate that aspirin and statins may favourably influence the risk of VTE, it is still not possible to draw up any practical recommendations.
- Published
- 2008
- Full Text
- View/download PDF
191. Association between antipsychotic drugs, antidepressant drugs, and venous thromboembolism.
- Author
-
Lacut K
- Subjects
- Adolescent, Adult, Age Factors, Aged, Antidepressive Agents pharmacology, Antipsychotic Agents pharmacology, Female, Humans, Male, Middle Aged, Venous Thromboembolism physiopathology, Young Adult, Antidepressive Agents adverse effects, Antipsychotic Agents adverse effects, Venous Thromboembolism chemically induced
- Published
- 2008
192. [Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial].
- Author
-
Couturaud F, Pernod G, Pison C, Mismetti P, Sanchez O, Meyer G, Parent F, Girard P, Simonneau G, Drouet L, Gueret P, Jego P, Delaval P, Duhamel E, Gruel Y, Delahousse B, Regina S, Pottier P, Connaud J, Lecomte F, Provost K, Vilmans N, Gosset X, Bura-Rivière A, Meach G, Lacut K, Bosson JL, Guillot K, Mottier D, and Leroyer C
- Subjects
- Anticoagulants administration & dosage, Anticoagulants adverse effects, Chi-Square Distribution, Data Interpretation, Statistical, Double-Blind Method, Hemorrhage chemically induced, Humans, Placebos, Practice Guidelines as Topic, Prognosis, Recurrence, Risk Assessment, Time Factors, Warfarin administration & dosage, Warfarin adverse effects, Anticoagulants therapeutic use, Pulmonary Embolism drug therapy, Venous Thromboembolism drug therapy, Vitamin K antagonists & inhibitors, Warfarin therapeutic use
- Abstract
Background: After stopping a 3 to 6 months course of oral anticoagulation for a first episode of idiopathic venous thromboembolism (VTE), the risk of recurrent VTE is high (10% per year). In this setting, international guidelines recommend at least 6 months treatment. However, this recommendation is not satisfactory for the following reasons: (1) no randomized trial has compared 6 months to extended duration (2 years) anticoagulation; and (2), even though the frequency of recurrent VTE is similar after pulmonary embolism (PE) and deep vein thrombosis (DVT), the fatality rate of recurrent VTE after PE is higher than that after DVT., Methods: A French multicentre double blind randomized trial. The main objective is to demonstrate, after a first episode of symptomatic idiopathic PE treated for 6 months using a vitamin K antagonist, that extended anticoagulation for 18 months (INR between 2 and 3) is associated with an increased benefit / risk ratio (recurrent VTE and severe anticoagulant-related bleeding) compared to placebo. The double blind evaluation is ensured using by active warfarin and placebo, and blinded INR. The protocol was approved by the ethics board of the Brest Hospital on the 7th of March 2006. For an alpha risk of 5% and a beta risk of 20%, the estimated sample size is 374 patients., Expected Results: This study has the potential to: (1) demonstrate that the benefit / risk ratio of extended anticoagulation for 18 months is higher than that observed with placebo in patients with a first episode of idiopathic PE initially treated for 6 months, during and after the treatment period; and (2) to validate or invalidate the contribution of isotope lung scans, lower limb Doppler ultrasound and D-Dimer at 6 months of treatment as predictors of recurrent VTE (medico-economic analysis included).
- Published
- 2008
- Full Text
- View/download PDF
193. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
- Author
-
Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, and Boschat J
- Subjects
- Aged, Angioplasty, Balloon, Coronary, Cell Adhesion Molecules metabolism, Clopidogrel, Double-Blind Method, Drug Antagonism, Drug Therapy, Combination, Female, Humans, Male, Microfilament Proteins metabolism, Middle Aged, Myocardial Infarction therapy, Omeprazole therapeutic use, Phosphoproteins metabolism, Phosphorylation, Platelet Aggregation drug effects, Prospective Studies, Proton Pump Inhibitors therapeutic use, Stents, Ticlopidine antagonists & inhibitors, Ticlopidine therapeutic use, Omeprazole pharmacology, Platelet Aggregation Inhibitors therapeutic use, Proton Pump Inhibitors pharmacology, Ticlopidine analogs & derivatives
- Abstract
Objectives: This trial sought to assess the influence of omeprazole on clopidogrel efficacy., Background: Clopidogrel has proved its benefit in the treatment of atherothrombotic diseases. In a previous observational study, we found clopidogrel activity on platelets, tested by vasodilator-stimulated phosphoprotein (VASP) phosphorylation, to be diminished in patients receiving proton pump inhibitor (PPI) treatment., Methods: In this double-blind placebo-controlled trial, all consecutive patients undergoing coronary artery stent implantation received aspirin (75 mg/day) and clopidogrel (loading dose, followed by 75 mg/day) and were randomized to receive either associated omeprazole (20 mg/day) or placebo for 7 days. Clopidogrel effect was tested on days 1 and 7 in both groups by measuring platelet phosphorylated-VASP expressed as a platelet reactivity index (PRI). Our main end point compared PRI value at the 7-day treatment period in the 2 groups., Results: Data for 124 patients were analyzed. On day 1, mean PRI was 83.2% (standard deviation [SD] 5.6) and 83.9% (SD 4.6), respectively, in the placebo and omeprazole groups (p = NS), and on day 7, 39.8% (SD 15.4) and 51.4% (SD 16.4), respectively (p < 0.0001)., Results: Omeprazole significantly decreased clopidogrel inhibitory effect on platelet P2Y12 as assessed by VASP phosphorylation test. Aspirin-clopidogrel antiplatelet dual therapy is widely prescribed worldwide, with PPIs frequently associated to prevent gastrointestinal bleeding. The clinical impact of these results remains uncertain but merits further investigation.
- Published
- 2008
- Full Text
- View/download PDF
194. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?
- Author
-
Lacut K, Le Gal G, Abalain JH, Mottier D, and Oger E
- Subjects
- Aged, Aged, 80 and over, Case-Control Studies, Databases, Factual, Female, Homocysteine blood, Humans, Hyperhomocysteinemia chemically induced, Male, Middle Aged, Risk Factors, Surveys and Questionnaires, Clofibric Acid adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Hyperhomocysteinemia epidemiology, Hypolipidemic Agents adverse effects, Venous Thromboembolism epidemiology
- Abstract
Background: Previous studies reported that statin use was associated with a decreased risk of venous thromboembolism (VTE), whereas no association was found between fibrate use and VTE. This report aims to test the hypothesis that part of these contrasting associations is related to total homocysteine level (tHcy)., Materials and Methods: This report from a case-control study included 677 cases hospitalised with confirmed VTE and no major acquired risk factor of VTE and their 677 controls. Statin and fibrate exposure was defined as a current use of drugs at admission. Fasting serum tHcy was measured in all patients., Results: The estimated odds ratio for VTE related to statin use was 0.53 (CI 95% 0.37-0.78), whereas it was 1.88 (CI 95% 1.29-2.74) for fibrate use. No difference was found for tHcy levels between patients who were current users of statin compared to non users (17.7 micromol/L+/-7.3 in users vs 18.4 micromol/L+/-8.4 in non users, p=0.50). In contrast, fibrate users had a significant higher mean level of tHcy than non users (23.2 micromol/L+/-8.7 in users vs 18.4 micromol/L+/-8.4 in non users, p<0.0001). Nevertheless, adjustment on tHcy level did not alter significance and strength of the association between fibrates and VTE (1.66, CI 95% 1.07-2.59)., Conclusions: Statin use was associated with a significant decreased risk of VTE, whereas fibrate use was associated with a significant increased risk of VTE. This last association was independent of tHcy levels.
- Published
- 2008
- Full Text
- View/download PDF
195. Primary prevention of venous thromboembolism in elderly medical patients.
- Author
-
Lacut K, Le Gal G, and Mottier D
- Subjects
- Aged, Aged, 80 and over, Global Health, Humans, Morbidity trends, Risk Factors, Survival Rate trends, Treatment Outcome, Venous Thromboembolism epidemiology, Anticoagulants therapeutic use, Primary Prevention methods, Venous Thromboembolism prevention & control
- Abstract
Primary prophylaxis with the use of an effective and safe intervention appears the best approach of venous thromboembolism (VTE) management in medical elderly patients, the most affected by VTE. With increasing life expectancy, prevention of VTE, particularly in elderly patients, will arise as a major public health problem. Few well designed clinical trials evaluating thromboprophylaxis in medical settings were conducted in the specific population of geriatric patients. However, among the several pharmacological treatments evaluated, low molecular weight heparins enoxaparin 40 mg daily or dalteparin 5000 IU daily appeared effective and safe in the prevention of VTE in elderly patients. Despite available data, and recommendations for VTE prevention in medical patients, thromboprophylaxis is underused or misused in practice. Heterogeneity of clinical studies, selected populations, concern about bleeding, and lack of a clear clinical benefit are some of the reasons that could explain the gap between theory and practice. In this review, after a brief report of epidemiologic data and specificities of VTE in elderly patients, the authors discuss the available results of VTE primary prevention trials for elderly medical patients, the limitations of these data, and the challenges to improve the practice and to reduce the incidence of this frequent but preventable disease.
- Published
- 2008
- Full Text
- View/download PDF
196. Family history as a risk factor for venous thromboembolism.
- Author
-
Noboa S, Le Gal G, Lacut K, Mercier B, Leroyer C, Nowak E, Mottier D, and Oger E
- Subjects
- Aged, Aged, 80 and over, Case-Control Studies, Family Health, Female, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Surveys and Questionnaires, Venous Thromboembolism etiology, Venous Thromboembolism genetics
- Abstract
Introduction: There are very few data assessing a family history of venous thromboembolism (VTE) as a risk factor for VTE. This question is nonetheless of interest as inherited risk factors are involved but at least partly unknown., Methods: The E.D.I.TH. study is a prospective hospital-based case-control study. The family history was assessed by using a standard questionnaire, considering the total number of the first-degree relatives and the number of these relatives who had suffered from VTE. We analysed 698 first VTE cases and their matched controls, 507 pairs without and 191 pairs with a major acquired risk factor (active malignancy, surgery or plaster cast in the past three months, pregnancy or delivery in the past three months)., Results: A family history of VTE was associated with VTE occurrence, irrespective of carrying or not factor V Leiden mutation or G20210A prothrombin gene mutation and irrespective of the presence or absence of major acquired risk factors; adjusted conditional odds ratio: 2.7 (95%CI, 1.8-3.8)., Conclusion: A family history might well be considered when estimating type and duration of prophylaxis for VTE specifically in patients with active cancer or who experienced surgery. Family history of VTE could be added to a prior VTE history to define a concept of clinical thrombophilia which is not necessarily related to carrying a known inherited risk factor.
- Published
- 2008
- Full Text
- View/download PDF
197. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study.
- Author
-
Lacut K, Le Gal G, Couturaud F, Cornily G, Leroyer C, Mottier D, and Oger E
- Subjects
- Adult, Aged, Case-Control Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Antidepressive Agents adverse effects, Antipsychotic Agents adverse effects, Venous Thromboembolism chemically induced
- Abstract
Cohort studies suggest that exposure to antipsychotic agents may be associated with an increased risk of venous thromboembolism (VTE). Few data concerning antidepressant drugs are available. Using a different methodological approach, the aim of this study was to estimate the association between neuroleptic and antidepressant drug use and the risk of VTE. We report the results of a case-control study designed to evaluate interactions between acquired and inherited risk factors of VTE. We included 677 cases hospitalized with deep vein thrombosis and or pulmonary embolism with no major acquired risk factor for VTE, and 677 controls matched for gender and age. Drug exposure was defined as current use of drugs at admission. Neuroleptic exposure was associated with an increased risk of VTE (OR = 2.1, 95% CI 1.4-3.2). Among neuroleptics, antipsychotic agent use was associated with a 3.5-fold increased risk of VTE (OR = 3.5, 95% CI 2.0-6.2). No association was found between antidepressant drug exposure and the risk of VTE (OR = 1.1, 95% CI 0.9-1.5). In this hospital-based case-control study, exposure to antipsychotic drugs was associated with an increased risk of VTE. These results, added to previous results, suggest that clinicians should consider antipsychotic drug exposure as a potential risk factor of VTE. More studies are needed in order to further elucidate this adverse effect, and to determine the possible predisposing factors and the biological mechanisms involved.
- Published
- 2007
- Full Text
- View/download PDF
198. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study.
- Author
-
Lacut K, Larramendy-Gozalo C, Le Gal G, Duchemin J, Mercier B, Gourhant L, Mottier D, Becquemont L, Oger E, and Verstuyft C
- Subjects
- Aged, Case-Control Studies, Factor V genetics, Female, Gene Frequency, Humans, Male, Middle Aged, Mutation, Odds Ratio, Polymorphism, Single Nucleotide, Prothrombin genetics, Risk Factors, Vitamin K Epoxide Reductases, Mixed Function Oxygenases genetics, Polymorphism, Genetic, Venous Thrombosis genetics
- Abstract
Background: The vitamin K epoxide reductase complex subunit 1 (VKORC1) recycles endogenous vitamin K, a cofactor for vitamin K-dependent coagulation factor synthesis. Common polymorphisms in VKORC1, the gene coding for VKORC1, have been found to affect the dose response to vitamin K antagonists, and to confer an increased risk of vascular diseases in a Chinese population. The aim of this study was to evaluate the association between the VKORC1 1173C > T polymorphism and venous thromboembolism (VTE)., Methods: We report the results of a case-control study designed to evaluate interactions between acquired and inherited risk factors of VTE. We studied 439 cases hospitalized with a first venous thromboembolic event that was not related to a major acquired risk factor for VTE, and 439 matched controls. The VKORC1 1173C > T polymorphism was selected for genotyping as the tagging single-nucleotide polymorphism for previously identified VKORC1 haplotypes., Results: The relationship between VTE and the VKORCI 1173C > T polymorphism was consistent with a recessive model. The frequency of the VKORCI TT genotype was lower in cases than in controls. The odds ratio (OR) (95% CI) was 0.62 (0.41-0.94) for the TT genotype as compared to CT/CC genotypes. Adjustment on cardiovascular diseases, body mass index, factor V (FV) and prothrombin gene mutations did not alter the results., Conclusions: In this case-control study, the frequency of the VKORCI TT genotype was lower in patients with VTE than in matched controls. The clinical consequence of these results remains to be determined, but gives new perspectives for exploration of the role of VKORCI polymorphism in the pathogenesis of VTE.
- Published
- 2007
- Full Text
- View/download PDF
199. Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality.
- Author
-
Lacut K, Le Gal G, Seizeur R, Prat G, Mottier D, and Oger E
- Subjects
- Aged, Cerebral Hemorrhage etiology, Female, Humans, Intermittent Pneumatic Compression Devices, Male, Middle Aged, Venous Thrombosis prevention & control, Cerebral Hemorrhage mortality, Platelet Aggregation Inhibitors adverse effects
- Abstract
Recent studies highlight the contribution of antiplatelet therapy to clinical severity and increased mortality of intracerebral hemorrhage (ICH) but results are discrepant. The aim of this report was to evaluate the association between antiplatelet drug use preceding the onset of ICH and the mortality, assessed at regular intervals, among patients with acute ICH. We analyzed data from a randomized study which enrolled consecutive patients with a documented acute ICH to evaluate the efficacy of intermittent pneumatic compression of the legs in venous thrombosis prevention. Clinical characteristics and treatment used before the onset of ICH were checked at the time of inclusion. Mortality was assessed at regular intervals until 3 months after ICH diagnosis. Among 138 patients included in this report, 30 were current users of antiplatelet therapy at the time of ICH; they were significantly older and less frequently heavy drinkers than non-users of antiplatelet drugs. Mortality rates were 20% at 8 days, 40% at 1 month, and 47% at 3 months among antiplatelet drug users compared with 6.5%, 13% and 19% among non-users. The corresponding estimated risks for mortality related to antiplatelet drug use were 3.6 (95% CI 1.1-12), 4.5 (95% CI 1.8-11), and 3.6 (95% CI 1.5-8.6). Adjusted for age, hypertension and alcohol over use, antiplatelet therapy remained significantly associated with an increased mortality rate of acute ICH. Current antiplatelet drug use preceding the onset of ICH is associated with increased short-term ICH mortality, independently of age.
- Published
- 2007
- Full Text
- View/download PDF
200. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.
- Author
-
Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, and Oger E
- Subjects
- Administration, Cutaneous, Administration, Oral, Aged, Biomarkers blood, Female, Humans, Middle Aged, Progesterone administration & dosage, Prospective Studies, Statistics, Nonparametric, Estrogen Replacement Therapy methods, Estrogens administration & dosage, Insulin-Like Growth Factor Binding Protein 3 blood, Insulin-Like Growth Factor I analysis, Postmenopause
- Abstract
Objective: Oestrogens can modulate the action or secretion of GH. Previous studies in postmenopausal women have shown a differential effect between transdermal 17beta-oestradiol and oral ethynyl-oestradiol on GH and IGF-1 concentrations. This secondary analysis, based on a large randomized trial, aimed to estimate the effect of the route of administration of 17beta-oestradiol in combined hormone replacement therapy with progesterone on IGF-1 and IGFBP-3 levels., Design: IGF-1 and IGFBP-3 were evaluated in a randomized study of 196 healthy postmenopausal women who were randomly allocated to receive on a continuous basis either 1 mg of 17beta-oestradiol orally combined with a daily intake of 100 mg progesterone (group 1; n = 63), or 50 microg of 17beta-oestradiol transdermally combined with a daily intake of 100 mg progesterone (group 2; n = 68), or triple dummy placebo (group 3; n = 65) over a 6-month period. IGF1 and IGFBP-3 levels were available for 133 women., Results: Oral oestrogen significantly decreased IGF-1 levels compared to placebo (P = 0.04) and transdermal oestrogen (P = 0.004), whereas transdermal oestrogen had no effect on IGF-1 levels compared to placebo (P = 0.56). As regards IGFBP-3, no significant difference was detected between the three groups., Conclusions: Our data indicate that the route of oestrogen administration can influence IGF-1 levels. IGF-1 concentrations decreased significantly with oral oestrogen, whereas no significant change was observed with transdermal oestrogen at 6 months. The clinical relevance of these differential effects remains to be determined, particularly with regard to the risk for cardiovascular diseases.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.